Heron Therapeutics, Inc. (NASDAQ:HRTX) has been given an average rating of “Buy” by the twelve brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and ten have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $29.71.

Several equities research analysts have commented on HRTX shares. Zacks Investment Research upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Wednesday, July 12th. Aegis restated a “buy” rating and set a $33.00 target price on shares of Heron Therapeutics in a research report on Tuesday, July 18th. Cantor Fitzgerald restated an “overweight” rating on shares of Heron Therapeutics in a research report on Monday, June 26th. Cowen and Company restated a “buy” rating and set a $40.00 target price on shares of Heron Therapeutics in a research report on Friday, May 26th. Finally, ValuEngine upgraded shares of Heron Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd.

Heron Therapeutics (HRTX) traded up 5.12% during trading on Friday, reaching $15.40. 1,200,703 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $15.87 and a 200 day moving average price of $14.95. Heron Therapeutics has a 52 week low of $12.21 and a 52 week high of $20.85. The firm’s market capitalization is $833.73 million.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.10. The company had revenue of $8.51 million for the quarter, compared to analysts’ expectations of $4.53 million. Equities research analysts forecast that Heron Therapeutics will post ($3.51) earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the stock. Parametric Portfolio Associates LLC boosted its position in shares of Heron Therapeutics by 2.3% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,910 shares of the biotechnology company’s stock worth $470,000 after buying an additional 771 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Heron Therapeutics by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 170,555 shares of the biotechnology company’s stock worth $2,363,000 after buying an additional 1,026 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Heron Therapeutics by 13.9% in the 1st quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after buying an additional 1,098 shares in the last quarter. HighTower Advisors LLC boosted its position in shares of Heron Therapeutics by 11.4% in the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after buying an additional 1,700 shares in the last quarter. Finally, Tudor Investment Corp ET AL boosted its position in shares of Heron Therapeutics by 10.2% in the 2nd quarter. Tudor Investment Corp ET AL now owns 18,618 shares of the biotechnology company’s stock worth $258,000 after buying an additional 1,724 shares in the last quarter.

TRADEMARK VIOLATION WARNING: “Heron Therapeutics, Inc. (HRTX) Receives Average Recommendation of “Buy” from Brokerages” was first reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/09/16/heron-therapeutics-inc-hrtx-receives-average-recommendation-of-buy-from-brokerages.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.